LOS ANGELES, Feb. 6, 2012 (GLOBE NEWSWIRE) -- C3 Jian, Inc.'s Board of Directors announced today that Duane A. Morris has been appointed Vice President of Production and Facilities, effective immediately. Mr. Morris is the Company's first senior management hire in the area of production management and brings with him over 30 years of experience in both establishing and managing manufacturing operations and related compliance issues. Mr. Morris has worked in all phases of commercial development and production scale-up for an array of products, including pharmaceuticals, vaccines and diagnostics.
"We are excited to recruit a person of Duane's caliber, who comes to C3 with a wealth of experience that will be invaluable as we gear up to make our own products," said Todd R. Patrick, C3 Jian's President and CEO. "This appointment is especially timely as we work to complete the improvements to our new research and development facility in Marina del Rey, which will feature GMP manufacturing capability."
Prior to joining C3 Jian, Mr. Morris was the Chief Operating Officer at Response Biomedical in Vancouver, Canada. While at Response Biomedical, Mr. Morris directed the expansion of manufacturing facilities and scale-up of in-vitro diagnostic products. Prior to his tenure at Response, Mr. Morris was responsible for all manufacturing and quality control activities for ID Biomedical Corporation until its acquisition by GlaxoSmithKline (GSK). Mr. Morris was then responsible for all North American Operations which included influenza vaccine production for GSK. Mr. Morris started his career at Syntex Corporation in Palo Alto, where he spent 21 years in increasingly responsible positions, ultimately becoming the Director of Pharmaceutical Manufacturing.
"I am thrilled to once again be involved with the development of an early-stage biopharmaceutical company," said Mr. Morris. "C3 Jian has huge potential and the strategy to maintain control over final production and quality control of the drug product is one that I am not only comfortable with, but think is critical to building success."
About C3 Jian, Inc.
C3 Jian, founded in 2005, is a clinical-stage biotechnology company developing and commercializing novel products to diagnose, treat and prevent diseases related to oral health. C3 is advancing targeted proprietary solutions, which can offer more selective, efficacious and safer treatment modalities for dental applications. The Company's platform cell signaling technology has potential applications beyond oral health and may impact a variety of diseases and disorders particularly related to bacterial and fungal infections. C3 Jian is based in Los Angeles, California.
For more information visit www.c3-jian.com.